Author: Head, Michael G; Fitchett, Joseph R; Cooke, Mary K; Wurie, Fatima B; Hayward, Andrew C; Lipman, Marc C; Atun, Rifat
Title: Investments in respiratory infectious disease research 1997–2010: a systematic analysis of UK funding Document date: 2014_3_26
ID: kbzh3trr_41_0
Snippet: There is also evidence of respiratory infection transmission at mass gatherings, such as the Hajj. 23 In addition to providing meningococcal and influenza vaccination for travellers, there should be investment in operational research to explore health system responsiveness to emerging threats and efficient ways to provide preventive medicines, as well as measuring the effectiveness of preventive therapies. There was very little funding for transl.....
Document: There is also evidence of respiratory infection transmission at mass gatherings, such as the Hajj. 23 In addition to providing meningococcal and influenza vaccination for travellers, there should be investment in operational research to explore health system responsiveness to emerging threats and efficient ways to provide preventive medicines, as well as measuring the effectiveness of preventive therapies. There was very little funding for translational research relating to pneumonia, a clear gap in the UK portfolio. Other vaccine-preventable diseases such as measles and pertussis, which are causes of high disease burden globally, also received very limited research funding despite there clearly being the need for translational and operational research. 16 The worldwide burden of drug-resistant tuberculosis is rapidly increasing, with WHO estimates of 630,000 cases of multidrug-resistant tuberculosis worldwide, great variation between countries, and emergence over the last decade of extensively drug-resistant cases. 24 Given the difficulties of developing a more effective vaccine, 25 the need for new diagnostics, therapeutics and targeted use of existing medicines becomes even more important. The reported resistance to antiviral drugs used 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 There is a paucity of research in antimicrobial resistance. 27 This is of concern, and has been highlighted by the UK Chief Medical Officer, 28, 29 with new funding for research related to antimicrobial resistance provided. 30 We believe that other funders should follow this lead. Most countries are under-investing in tuberculosis R&D 31 33 It should also be noted that considerations other than incidence should ultimately influence the allocation of resources. Such considerations may include the prevalence and predicted impact of the disease, how treatable the disease is (antibiotic courses and combinations are very different between pneumonia and tuberculosis), co-factors and co-morbities (e.g. Our study has several limitations, which have been highlighted and discussed in detail elsewhere. 16 There was little publicly-available data from the pharmaceutical industry. Hence, there is a data gap in relation to funding of clinical trials and development of vaccines and diagnostics, which the 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 F o r p e e r r e v i e w o n l y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1
Search related documents:
Co phrase search for related documents- antimicrobial resistance and clear gap: 1, 2
- antimicrobial resistance and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- antimicrobial resistance and data gap: 1, 2, 3
- antimicrobial resistance research paucity and clear gap: 1, 2
- antimicrobial resistance research paucity and data gap: 1, 2
- antiviral drug and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral drug and data gap: 1
- antiviral drug and development clinical trial: 1
- antiviral drug and diagnostic vaccine: 1, 2, 3
- clear gap and data gap: 1, 2
- clinical trial and data gap: 1, 2, 3, 4, 5
- clinical trial and development clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and diagnostic vaccine: 1, 2, 3
- detail discuss and diagnostic vaccine: 1
Co phrase search for related documents, hyperlinks ordered by date